Aim To evaluate the effect of strontium ranelate in treatment of women with glucocorticoidinduced osteoporosis.
Methods There were examined 241 women with glucocorticoidinduced osteoporosis (average age 59,6±11,1 years, average height 161,3±6,4 cm, average weight 70,4±12,8 kg).
Evaluation of pain syndrome and level of physical activity was carried out with visual analogue scale (VAS). Examination was performed before onset of treatment and after a four, eight and twelve month treatment course. Strontium ranelate (Bivalos, “Servier”) was taken in a dose of one 2 g sachet as a suspension in water once a day and 1 tablet of Calcemin-advance (Calcium – 500 mg, Vit. D – 400 IU) 2 times a day during 12 months.
Results The patients had the risk factors of osteoporosis: 24% of patients had osteoporotic fractures in their anamnesis; 19% – hip fractures in mother or father of patients and 28% – smoking. We observed a reliable decrease of vertebral pain syndrome after four months of treatment by 14%, after eight months – 35%; after twelve months – 47% (d<0.00001) and increase of functional abilities of patients after four months of treatment by 47%, after eight months – 86%; after twelve months – 100% (d<0.00001).
Conclusions It has been demonstrated that strontium ranelate treatment significantly decreases pronounced vertebral pain syndrome and improves functional abilities of women with glucocorticoidinduced osteoporosis.
Disclosure of Interest None Declared.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.